IFC Holdings’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

IFC Holdings’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,081	Closed	-$253K	–	536
2017 Q2	$253K	Buy	+2,081	New	+$241K	0.02%	412

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

IFC Holdings's ICPT Position: Q3 2017 in Review

IFC Holdings sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2017, closing a stake of 2,081 shares — an estimated $253K sold.

IFC Holdings first reported a position in ICPT in Q2 2017 and held it in 1 quarter. The position peaked at $253K in Q2 2017. 155 funds tracked by Wall St. Rank hold ICPT as of Q3 2017.

IFC Holdings reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
IFC Holdings sold 2,081 Intercept Pharmaceuticals, Inc. shares in Q3 2017, an estimated $253K.
IFC Holdings first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
IFC Holdings's Intercept Pharmaceuticals, Inc. position peaked at $253K in Q2 2017.
155 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2017.

Based on IFC Holdings's 13F filing for Q3 2017, filed 26 Oct 2017.